Name
Competence Centre for Cancer Research AS
Registry code
11015418
VAT number
EE100883541
Type
AS - Joint Stock Company
Status
Registered
Foundation date
13.02.2004 (20)
Financial year
01.01-31.12
Capital
50 000.00 €
Activity
70221 - Business and other management consultancy activities
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| AS Bravo Pharmaceuticals 14159974 | 65% - 32 500.00 EUR | - | - | Shareholder |
| Rakesh Pandey 10.12.1977 (46) | - | Board member | - | |
| Reena Singh 13.03.1978 (46) | - | - | Indirect ownership | Board member |
| Ivo Nagel 07.09.1977 (47) | - | - | - | Board member |
| Nishant Kumar 18.10.1983 (41) | - | - | - | Board member |
| Aldago OÜ 10654228 | - | - | - | Founder |
| Andres Valkna 01.07.1969 (55) | - | - | - | Founder |
| Priit Kogerman 13.05.1967 (57) | - | - | - | Founder |
| Riin Ehin 12.01.1968 (56) | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| MTÜ Personalised Medicine Association 80561497 | - | - | - | Founder (without contribution) |
| 2019 05.05.2021 | 2020 10.09.2021 | 2021 22.06.2022 | 2022 26.09.2023 | |
|---|---|---|---|---|
| Total Revenue | 71 718 € | 53 269 € | 2 758 € | 0 € |
| Net profit (loss) for the period | 52 878 € | -32 563 € | -617 € | 129 € |
| Profit Margin | 74% | -61% | -22% | - |
| Current Assets | 98 999 € | 100 836 € | 101 195 € | 101 236 € |
| Fixed Assets | 3 148 € | 30 056 € | 29 080 € | 29 080 € |
| Total Assets | 102 147 € | 130 892 € | 130 275 € | 130 316 € |
| Current Liabilities | 3 792 € | 100 € | 100 € | 12 € |
| Non Current Liabilities | 0 € | 65 000 € | 65 000 € | 65 000 € |
| Total Liabilities | - | 65 100 € | 65 100 € | 65 012 € |
| Share Capital | 50 000 € | 50 000 € | 50 000 € | 50 000 € |
| Equity | 98 355 € | 65 792 € | 65 175 € | 65 304 € |
| Employees | 1 | 1 | 0 | 0 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 14 000 € | - | - | - |
| 2023 Q4 | 19 500 € | - | 463.75 € | - |
| 2023 Q3 | - | - | - | - |
| 2023 Q2 | - | - | - | - |
| 2023 Q1 | - | - | - | - |
| 2022 Q4 | - | - | - | - |
| 2022 Q3 | - | - | - | - |
| 2022 Q2 | - | - | - | - |
| 2022 Q1 | - | - | - | - |
| 2021 Q4 | 508.33 € | 101.92 € | - | - |
| 2021 Q3 | 2 250 € | 450 € | - | - |
| 2021 Q2 | - | - | - | - |
| 2021 Q1 | - | - | - | 1 |
| 2020 Q4 | - | - | - | 1 |
| 2020 Q3 | - | 335.15 € | 333.9 € | 1 |
| 2020 Q2 | 8 750 € | - | 1 001.7 € | 1 |
| 2020 Q1 | 52 000 € | - | 1 001.7 € | 1 |
